Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.54 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TNKS | O95271 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | WNT3A | P56704 | 1/20 | 0.40 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14153754 | 0.96 | KMT2A (0.54) | KMT2AL3MBTL1NPY5RSMPD3KDM4E | |
| SCHEMBL15913449 | 0.86 | KMT2A (0.44) | KMT2AL3MBTL1NPY5RSMPD3KDM4E | |
| SCHEMBL14153752 | 0.82 | SMPD3 (0.49) | KMT2AL3MBTL1NPY5RSMPD3KDM4E | |
| SCHEMBL25220187 | 0.82 | SMPD3 (0.49) | KMT2AL3MBTL1NPY5RSMPD3KDM4E | |
| SCHEMBL11844688 | 0.78 | TNKS2 (0.50) | KMT2AL3MBTL1SMPD3NPC1RAB9A | |
| SCHEMBL8319716 | 0.77 | PDCD1 (0.53) | KMT2AL3MBTL1NPY5RKDM4EALDH1A1 | |
| SCHEMBL12492799 | 0.77 | PDCD1 (0.68) | KMT2AL3MBTL1NPY5RKDM4EALDH1A1 | |
| SCHEMBL30319470 | 0.76 | NPY5R (0.39) | KMT2AL3MBTL1NPY5RSMPD3KDM4E | |
| SCHEMBL25120538 | 0.76 | NPY5R (0.39) | KMT2AL3MBTL1NPY5RSMPD3KDM4E | |
| SCHEMBL1032502 | 0.76 | TNKS2 (0.68) | KMT2AL3MBTL1KDM4EALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6797824-B2 | UEFUL IN THE DIAGNOSIS AND THERAPY OF AFFECTIVE DISORDERS SUCH AS SCHIZOPHRENIA AND DEPRESSION AS WELL AS CERTAIN MOVEMENT DISORDERS SUCH AS PARKINSONISM | NEUROGEN CORPORATION | 2004-09-28 | — | — | US | disclosed |
| US-20030018025-A1 | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands | NEUROGEN CORPORATION, CORPORATION OF THE STATE OF DELAWARE | 2003-01-23 | — | — | US | disclosed |
| US-20020143044-A1 | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands | NEUROGEN CORPORATION | 2002-10-03 | — | — | US | disclosed |
| US-6358955-B1 | SCHIZOPHRENIA, PSYCHOLOGICAL DISORDERS, PARKINSON*S DISEASE; ANTIDEPRESSANTS | NEUROGEN CORPORATION | 2002-03-19 | — | — | US | disclosed |
| US-6069251-A | HIGHLY SELECTIVE PARTIAL AGONISTS OR ANTAGONISTS AT BRAIN DOPAMINE RECEPTOR SUBTYPES OR PRODRUGS; DIAGNOSIS AND TREATMENT SCHIZOPHRENIA; ANTIDEPRESSANTS; CERTAIN MOVEMENT DISORDERS SUCH AS PARKINSONISM. | NEUROGEN CORPORATION (US) | 2000-05-30 | — | — | US | disclosed |
| US-5712392-A | DOPAMINERGIC AGENTS TREATING SCHIZOPHRENIA, ANTIDEPRESSANTS FOR PARKINSON'S DISEASE | NEUROGEN CORPORATION (US) | 1998-01-27 | — | — | US | disclosed |
| EP-0793653-A1 | CERTAIN 4-AMINOMETHYL-2-SUBSTITUTED IMIDAZOLE DERIVATIVES AND 2-AMINOMETHYL-4-SUBSTITUTED IMIDAZOLE DERIVATIVES; NEW CLASSES OF DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1997-09-10 | — | — | EP | disclosed |
| US-5656762-A | TREATING SCHIZOPHRENIA, DEPRESSION, PARKINSON*S DISEASE | NEUROGEN CORPORATION (US) | 1997-08-12 | — | — | US | disclosed |
| US-5646281-A | FOR USE IN THE DIAGNOSIS AND TREATMENT OF SCHIZOPHRENIA, DEPRESSION AND PARKINSON*S DISEASE | NEUROGEN CORPORATION (US) | 1997-07-08 | — | — | US | disclosed |
| US-5633377-A | DIAGNOSIS, THERAPY OF SCHIZOPHRENIA, DEPRESSION, PARKINSON'SDISEASE | NEUROGEN CORPORATION (US) | 1997-05-27 | — | — | US | disclosed |
| WO-1996016040-A1 | CERTAIN 4-AMINOMETHYL-2-SUBSTITUTED IMIDAZOLE DERIVATIVES AND 2-AMINOMETHYL-4-SUBSTITUTED IMIDAZOLE DERIVATIVES; NEW CLASSES OF DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1996-05-30 | — | — | WO | disclosed |
| US-3987054-A | CORROSION INHIBITORS | PLIVA PHARMACEUTICAL AND CHEMICAL WORKS (YU) | 1976-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018025-A1 | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands | CHRNA4, GRIA4, OPRM1 | KMT2A 1287/4885L3MBTL1 2338/4885NPY5R 190/4885 |
| US-20020143044-A1 | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands | DRD2, OPRM1, OPRD1 | KMT2A 1336/4885L3MBTL1 2458/4885NPY5R 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.